| Document |
Document Title |
|
WO/2017/129069A1 |
The present invention falls within the field of chemical pharmaceutical techniques, and in particular provides the preparation of a tetrahydroquinoline-related bicyclic compound and use thereof, wherein the compound has the structure as ...
|
|
WO/2017/125093A1 |
Disclosed are a hydroquinone compound, a preparation method therefor, and an application in tumour resistance or immunomodulation. The structural formula of the hydroquinone compound is as shown in formula I, wherein: X is C=O or CH2; Y ...
|
|
WO/2017/122209A2 |
Disclosed herein are compounds capable of inhibiting dimerization of NF-κB, for example, p65-p65 homodimerization and/or p50-p65 heterodimerization, the compounds being represented by formula I: X-L2-L1-L'2-Y Formula I wherein X, Y, L1,...
|
|
WO/2017/114052A1 |
Disclosed are a high stress resistant plant growth regulator and a preparation method and use thereof. In particular, the compound provided by the present invention is an ABA substitute for significantly improving the stress resistance o...
|
|
WO/2017/116558A1 |
The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and ...
|
|
WO/2017/108152A1 |
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.
|
|
WO/2017/109095A1 |
The invention relates to (hetero) cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
|
|
WO/2017/102063A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2017/104294A1 |
The purpose of the present invention is to provide an oxazine compound that is characterized by having a group that has an aromatic ring structure and multiple specified carbon-carbon double bond structures. Further, a composition includ...
|
|
WO/2017/104295A1 |
The purpose of the present invention is to provide an oxazine compound that is characterized by having a group that has an aromatic ring structure and multiple specified carbon-carbon double bond structures. Further, a composition includ...
|
|
WO/2017/098927A1 |
The present invention provides an oxazine compound having a specific structure, which is characterized by including a group having: an aromatic ring structure; and a plurality of specified carbon-carbon triple bond structures. The presen...
|
|
WO/2017/093157A1 |
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof wherein ASC is Ring A represents a 4- to 6-membered saturated ring containing carbon atoms as ring members in additio...
|
|
WO/2017/095732A1 |
Described herein is an unsaturated fluorinated compound of formula (I) where X is O or N; Y is F or H; Z is F or CF3; and A is F or CF3 wherein when X is O, then n is 1, Y is H, Z is F, A is F, and Rf is a linear or branched perfluorinat...
|
|
WO/2017/070796A1 |
The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic n...
|
|
WO/2017/070718A1 |
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...
|
|
WO/2017/066699A1 |
The invention includes methods and materials for forming and manipulating aromatic-based polymers and copolymers using biomass compounds as starting materials. Embodiments of the invention can be used in processes designed to replace tho...
|
|
WO/2017/064350A1 |
The invention relates to a new family of six-membered benzo-heterocycles having oxygen and nitrogen atoms, joined to substituted purines, halogens and triazoles which are useful in cancer treatment, in particular in treatments whose ther...
|
|
WO/2017/056115A1 |
The present invention provides novel N-aryl containing fused heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/ degraders and process for their preparation.
|
|
WO/2017/049409A1 |
Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycosid...
|
|
WO/2017/049245A2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2017/040965A1 |
A lubricant composition includes a base oil present in an amount of greater than 70 parts by weight per 100 parts by weight of the lubricant composition and an antioxidant. The antioxidant has the structure: wherein each X is independent...
|
|
WO/2017/040963A1 |
The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2', L, X, W, Y1,Y2, Y3, and Y4 are described herein.
|
|
WO/2017/028940A1 |
The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or a...
|
|
WO/2017/028941A1 |
The present invention relates to the compounds of the formulae (1) and (2) and to organic electroluminescent devices, in particular blue- emitting devices, in which these compounds are used as host material or dopant in the emitting laye...
|
|
WO/2017/024229A1 |
A process for the stereoselective synthesis of chiral 3-heterocyclyl-1,2-dihydroxy cyclohexanes is disclosed. The process involves reacting a tricyclic nitrogenous heterocycle with an allyl carbonate in the presence of a chiral palladium...
|
|
WO/2017/018476A1 |
Provided is a crystal of a quinazoline derivative. The present invention relates to an acid addition salt of a compound represented by formula (I), and a pharmaceutical composition and the like which contain the acid addition salt.
|
|
WO/2017/018751A1 |
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. I...
|
|
WO/2017/017505A1 |
Invention is related to novel compounds – benzenesulfonamides of general formulas (I) and (II). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...
|
|
WO/2017/018750A1 |
The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. I...
|
|
WO/2017/014546A1 |
The present invention relates to a luminescent material for delayed fluorescence and an organic electroluminescent device comprising the same. By using the luminescent material for delayed fluorescence according to the present invention,...
|
|
WO/2017/012890A1 |
The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.
|
|
WO/2017/010399A1 |
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...
|
|
WO/2016/210134A1 |
A method of treating cancer in a subject in need thereof includes administering to the subject therapeutically effective amounts of a PP2A activator and a protein kinase inhibitor.
|
|
WO/2016/208775A1 |
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep d...
|
|
WO/2016/204276A1 |
[Problem] To provide a substrate solution for lipase activity measurement, a lipase activity measurement reagent, and an emulsion solution having excellent storage stability. Also to provide a method for measuring the lipase activity in ...
|
|
WO/2016/203773A1 |
Provided is an electrochromic compound represented by the following general formula (I) or (II) where R1 to R13 are each independently a hydrogen atom, a halogen atom, a monovalent organic group, or a polymerizable functional group, and ...
|
|
WO/2016/197730A1 |
The present invention relates to an organic electroluminescent material, which has a structure as represented by formula (I). Compounds as represented by formula (I) have highly stable electron acceptor groups and electron donor groups, ...
|
|
WO/2016/201225A1 |
The invention provides aryl dihydro-2H-benzo[b] [l,4]oxazine sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treat...
|
|
WO/2016/198374A1 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2016/198937A1 |
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds...
|
|
WO/2016/198691A1 |
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein ASC is -N(R8)(R9)ASC-1 ASC-1 is Ring A represents a 4- to 6-membered saturated ring containing carbon atoms ...
|
|
WO/2016/180751A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2016/181846A1 |
In order to provide a novel π-conjugated compound capable of increasing the light-emission efficiency of an organic electroluminescence element, for example, this π-conjugated compound has a structure indicated by general formula (1). ...
|
|
WO/2016/173020A1 |
A conjugated compound containing a diphenyl sulfone phenyl structure, a method for preparing same, and use for fabricating a light emitting layer or an electronic transmission layer of an organic electroluminescent diode. The compound ha...
|
|
WO/2016/161279A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2016/089182A9 |
The present invention relates to a polybenzoxazine precursor and a method for preparing the same and, more specifically, to a polybenzoxazine precursor and a method for preparing the same, wherein the polybenzoxazine precursor can be pre...
|
|
WO/2016/145153A1 |
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associat...
|
|
WO/2016/143652A1 |
Provided is a compound that exhibits an excellent controlling effect against harmful arthropods. A 3-aminooxalylaminobenzamide compound represented by formula (1) has an excellent controlling effect against harmful arthropods. [In the fo...
|
|
WO/2016/141257A1 |
The present disclosure provides an organic sulfur acid-free composition containing a benzoxazine, phenolic compound and nitrogen-containing heterocyclic compound. The organic sulfur acid-free composition, upon curing at temperatures as l...
|
|
WO/2016/127661A1 |
Provided is a synthesis process for a chiral cyclopropyl ethynyl tertiary alcohol compound. With regard to the process of the present invention, a chiral amino alcohol or a chiral amino diol is reacted as a ligand in the presence of an a...
|
